Skip to content
-
Subscribe to our newsletter & never miss our best posts. Subscribe Now!
Itfy.in

At Itfy, we are dedicated to revolutionizing the way you receive news. Our mission is to provide timely, accurate, and personalized news updates using cutting-edge AI technology. Stay informed, stay ahead with us.

Itfy.in

At Itfy, we are dedicated to revolutionizing the way you receive news. Our mission is to provide timely, accurate, and personalized news updates using cutting-edge AI technology. Stay informed, stay ahead with us.

  • Home
  • News Updates
    • Latest News
    • Entertainment News
    • Northeast News
  • Technology
    • Digital Transformation
    • Artificial Intelligence
    • Machine Learning
    • Generative AI
    • Cybersecurity
  • Education & Growth
    • Education
    • Lifelong Learning
    • Parenting
    • Career Growth
  • Startup & Entrepreneurship
    • Remote Work
    • Startups
    • Digital Marketing
    • Social Media
    • Entrepreneurship
    • Lean Thinking
    • Personal Finance
  • Climate Justice
    • Climate Tech
  • Health & Wellness
    • Mental Health
  • Tourism
  • Home
  • News Updates
    • Latest News
    • Entertainment News
    • Northeast News
  • Technology
    • Digital Transformation
    • Artificial Intelligence
    • Machine Learning
    • Generative AI
    • Cybersecurity
  • Education & Growth
    • Education
    • Lifelong Learning
    • Parenting
    • Career Growth
  • Startup & Entrepreneurship
    • Remote Work
    • Startups
    • Digital Marketing
    • Social Media
    • Entrepreneurship
    • Lean Thinking
    • Personal Finance
  • Climate Justice
    • Climate Tech
  • Health & Wellness
    • Mental Health
  • Tourism
Close

Search

  • https://www.facebook.com/
  • https://twitter.com/
  • https://t.me/
  • https://www.instagram.com/
  • https://youtube.com/
Subscribe
Home/News/Breakthrough Joy: Eli Lilly’s Zepbound Dramatically Reduces Heart Failure Risks in Latest Study
News

Breakthrough Joy: Eli Lilly’s Zepbound Dramatically Reduces Heart Failure Risks in Latest Study

By adminitfy
August 1, 2024 2 Min Read

Eli Lilly & Co.’s weight loss drug, Zepbound, has demonstrated significant benefits for patients with heart failure and obesity, according to late-stage trial data released by the company. The findings suggest that GLP-1 drugs like Zepbound, traditionally known for aiding weight loss and blood sugar regulation, may also offer broader health benefits. This could potentially lead to expanded insurance coverage for such treatments.

In the trial, Zepbound reduced the risk of hospitalization or death due to heart complications by 38% compared to a placebo. It also improved heart failure symptoms and physical limitations. The study included over 700 patients with heart failure with preserved ejection fraction (HFpEF) and obesity, some of whom had diabetes. HFpEF involves the heart’s inability to pump sufficient blood, leading to significant symptoms and physical limitations.

Eli Lilly plans to submit the trial results to U.S. and international regulators later this year. The announcement boosted Eli Lilly’s shares by over 3% in Thursday morning trading. The company will present the data at an upcoming medical meeting and aims to publish it in a peer-reviewed journal.

The safety profile of Zepbound was consistent with previous trials, with mild to moderate gastrointestinal side effects such as nausea and diarrhea. Eli Lilly’s main competitor, Novo Nordisk, has already applied to use its weight loss drug Wegovy for treating patients with HFpEF. Both companies are exploring their drugs’ efficacy in treating chronic kidney disease and fatty liver disease.

Zepbound targets both the GLP-1 and GIP hormone receptors, while Wegovy focuses solely on GLP-1, offering a potentially broader treatment mechanism.

Original Story https://www.cnbc.com/2024/08/01/eli-lilly-weight-loss-drug-zepbound-cuts-heart-failure-risks-in-study.html
Category :
Tags:

Author

adminitfy

Follow Me
Other Articles
Previous

Tragic Outbreak: Japanese Encephalitis Claims 22 Lives at GMCH in Just Four Months

Next

<p>"<em>Shocking! Toshu and Aadhya Turn Evil: Devastating Plans to Ruin Anu-Anuj’s Lives</em>"</p>

Search...

Recent Posts

  • California Summons Nvidia Over Former CEO's China Ties
    California Summons Nvidia Over Former CEO’s China Ties
    by adminitfy
    November 20, 2026
  • Empowering Northeast India: CII’s CSR Connect Event Ignites Social Development
    by adminitfy
    July 3, 2024
  • Urgent Crisis: Northeast on High Alert as Death Toll Tragically Rises in Assam
    by adminitfy
    July 3, 2024
  • Triumphant Breakthrough: Security Forces Successfully Capture 4 Insurgents in Manipur Operation
    by adminitfy
    July 3, 2024

Welcome to the ultimate source for fresh perspectives! Explore curated content to enlighten, entertain and engage global readers.

  • Facebook
  • X
  • Instagram
  • LinkedIn

Latest Posts

  • California Summons Nvidia Over Former CEO’s China Ties
  • The AI Buildout’s Hidden Infrastructure Bill: Power, Permits, and Public Trust
  • Governor Reviews Pakyong’s Major Development Initiatives and Projects
  • Bidya Rao: Four Decades of Brilliance in Assamese and Bengali Cinema
  • Suboptimal Vaccination Rates Fuel Widespread U.S. Measles Outbreaks
  • November 2026 (612)
  • October 2026 (646)
  • September 2026 (524)
  • August 2026 (1001)
  • July 2026 (986)
  • June 2026 (963)
  • May 2026 (922)
  • April 2026 (1525)
  • March 2026 (1522)
  • February 2026 (1252)
  • January 2026 (968)
  • December 2025 (942)
  • November 2025 (853)
  • October 2025 (869)
  • September 2025 (733)
  • August 2025 (810)
  • July 2025 (720)
  • June 2025 (1244)
  • May 2025 (2201)
  • April 2025 (1481)
  • March 2025 (2020)
  • February 2025 (1159)
  • January 2025 (1440)
  • December 2024 (1499)
  • November 2024 (1771)
  • October 2024 (1815)
  • September 2024 (1750)
  • August 2024 (1458)
  • July 2024 (1268)

Contact

Email

info@itfy.in

Location

INDIA

Copyright 2026 — Itfy.in. All rights reserved.